• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在急性呼吸窘迫综合征实验模型中作为药物载体的吸入式半氟化烷烃(SFA)

Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome.

作者信息

Otto Matthias, Krebs Jörg, Welker Peter, Holm René, Thiel Manfred, Gattinoni Luciano, Quintel Michael, Tsagogiorgas Charalambos

机构信息

Department of Anaesthesiology and Critical Care Medicine, University Hospital Mannheim, Faculty of Medicine, University of Heidelberg, Theodor-Kutzer Ufer 1-3, 68165 Mannheim, Germany.

Drug Product Development, Janssen Research and Development, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium.

出版信息

Pharmaceutics. 2021 Mar 23;13(3):431. doi: 10.3390/pharmaceutics13030431.

DOI:10.3390/pharmaceutics13030431
PMID:33806903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8004724/
Abstract

Aerosol therapy in patients suffering from acute respiratory distress syndrome (ARDS) has so far failed in improving patients' outcomes. This might be because dependent lung areas cannot be reached by conventional aerosols. Due to their physicochemical properties, semifluorinated alkanes (SFAs) could address this problem. After induction of ARDS, 26 pigs were randomized into three groups: (1) control (Sham), (2) perfluorohexyloctane (F6H8), and (3) F6H8-ibuprofen. Using a nebulization catheter, (2) received 1 mL/kg F6H8 while (3) received 1 mL/kg F6H8 with 6 mg/mL ibuprofen. Ibuprofen plasma and lung tissue concentration, bronchoalveolar lavage (BAL) fluid concentration of TNF-α, IL-8, and IL-6, and lung mechanics were measured. The ibuprofen concentration was equally distributed to the dependent parts of the right lungs. Pharmacokinetic data demonstrated systemic absorption of ibuprofen proofing a transport across the alveolo-capillary membrane. A significantly lower TNF-α concentration was observed in (2) and (3) when compared to the control group (1). There were no significant differences in IL-8 and IL-6 concentrations and lung mechanics. F6H8 aerosol seemed to be a suitable carrier for pulmonary drug delivery to dependent ARDS lung regions without having negative effects on lung mechanics.

摘要

迄今为止,急性呼吸窘迫综合征(ARDS)患者的雾化治疗未能改善患者的预后。这可能是因为传统气雾剂无法到达肺低垂区域。由于其物理化学性质,半氟化烷烃(SFAs)可以解决这个问题。诱导ARDS后,将26头猪随机分为三组:(1)对照组(假手术组),(2)全氟己基辛烷(F6H8)组,和(3)F6H8-布洛芬组。使用雾化导管,(2)组接受1 mL/kg F6H8,而(3)组接受1 mL/kg F6H8与6 mg/mL布洛芬的混合物。测量布洛芬的血浆和肺组织浓度、支气管肺泡灌洗(BAL)液中TNF-α、IL-8和IL-6的浓度以及肺力学。布洛芬浓度在右肺低垂部位均匀分布。药代动力学数据表明布洛芬存在全身吸收,证明其可穿过肺泡-毛细血管膜。与对照组(1)相比,(2)组和(3)组中TNF-α浓度显著降低。IL-8和IL-6浓度以及肺力学方面无显著差异。F6H8气雾剂似乎是将药物输送到ARDS肺低垂区域的合适载体,且对肺力学无负面影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/c128816a2c05/pharmaceutics-13-00431-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/f6efbd4852d9/pharmaceutics-13-00431-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/10b13cc99eb0/pharmaceutics-13-00431-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/c128816a2c05/pharmaceutics-13-00431-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/f6efbd4852d9/pharmaceutics-13-00431-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/10b13cc99eb0/pharmaceutics-13-00431-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce7a/8004724/c128816a2c05/pharmaceutics-13-00431-g003.jpg

相似文献

1
Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome.在急性呼吸窘迫综合征实验模型中作为药物载体的吸入式半氟化烷烃(SFA)
Pharmaceutics. 2021 Mar 23;13(3):431. doi: 10.3390/pharmaceutics13030431.
2
Semifluorinated alkanes--a new class of excipients suitable for pulmonary drug delivery.半氟化烷烃——一类适合肺部给药的新型辅料。
Eur J Pharm Biopharm. 2010 Sep;76(1):75-82. doi: 10.1016/j.ejpb.2010.05.011. Epub 2010 Jun 2.
3
Aerosolized semifluorinated alkanes as excipients are suitable for inhalative drug delivery--a pilot study.半氟化烷烃气溶胶作为赋形剂适合吸入性药物传递-初步研究。
Int J Pharm. 2012 Jan 17;422(1-2):194-201. doi: 10.1016/j.ijpharm.2011.10.051. Epub 2011 Nov 7.
4
Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.全氟烷烃作为用于局部眼部给药的液体药物载体系统。
Eur J Pharm Biopharm. 2014 Sep;88(1):123-8. doi: 10.1016/j.ejpb.2014.05.009. Epub 2014 May 15.
5
Impact of different emulsifiers on biocompatibility and inflammatory potential of Perfluorohexyloctane (F6H8) emulsions for new intravenous drug delivery systems.不同乳化剂对用于新型静脉给药系统的全氟己基辛烷(F6H8)乳液的生物相容性和炎症潜力的影响。
Drug Des Devel Ther. 2019 Jun 27;13:2097-2110. doi: 10.2147/DDDT.S195954. eCollection 2019.
6
Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.基于半氟化烷的系统可增强难溶性药物对角膜的渗透。
Int J Pharm. 2018 Mar 1;538(1-2):119-129. doi: 10.1016/j.ijpharm.2018.01.019. Epub 2018 Jan 12.
7
Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications.半氟化烷烃作为新型药物载体——潜在医学及临床应用综述
Pharmaceutics. 2023 Apr 11;15(4):1211. doi: 10.3390/pharmaceutics15041211.
8
Evaluation of pharmacokinetic properties and anaesthetic effects of propofol in a new perfluorohexyloctane (F6H8) emulsion in rats--A comparative study.新型全氟己基辛烷(F6H8)乳剂中丙泊酚在大鼠体内的药代动力学特性及麻醉效果评估——一项对比研究。
Int J Pharm. 2015;486(1-2):69-76. doi: 10.1016/j.ijpharm.2015.03.037. Epub 2015 Mar 19.
9
Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome.成人呼吸窘迫综合征中肿瘤坏死因子α与白细胞介素10的相对产生量
Thorax. 1997 May;52(5):442-6. doi: 10.1136/thx.52.5.442.
10
Semi-fluorinated alkanes as carriers for drug targeting in acute respiratory failure.半氟化烷烃作为急性呼吸衰竭中药物靶向的载体。
Exp Lung Res. 2010 Oct;36(8):499-507. doi: 10.3109/01902141003721457.

引用本文的文献

1
Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications.半氟化烷烃作为新型药物载体——潜在医学及临床应用综述
Pharmaceutics. 2023 Apr 11;15(4):1211. doi: 10.3390/pharmaceutics15041211.

本文引用的文献

1
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
2
Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.2019 年冠状病毒病的高凝和抗血栓治疗:新的挑战。
Thromb Haemost. 2020 Jun;120(6):949-956. doi: 10.1055/s-0040-1710317. Epub 2020 Apr 29.
3
Management of COVID-19 Respiratory Distress.新型冠状病毒肺炎呼吸窘迫的管理
JAMA. 2020 Jun 9;323(22):2329-2330. doi: 10.1001/jama.2020.6825.
4
Thromboinflammation and the hypercoagulability of COVID-19.新冠病毒感染的血栓炎症与高凝状态
J Thromb Haemost. 2020 Jul;18(7):1559-1561. doi: 10.1111/jth.14849. Epub 2020 May 26.
5
Metabolism of Ibuprofen in Growing Conventional Pigs: A Pharmacokinetic Approach.布洛芬在生长中的普通猪体内的代谢:一种药代动力学方法。
Front Pharmacol. 2019 Jun 27;10:712. doi: 10.3389/fphar.2019.00712. eCollection 2019.
6
Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis.急性呼吸窘迫综合征的肺液生物标志物:系统评价和荟萃分析。
Crit Care. 2019 Feb 12;23(1):43. doi: 10.1186/s13054-019-2336-6.
7
Extravascular lung water measurements in acute respiratory distress syndrome: why, how, and when?急性呼吸窘迫综合征的血管外肺水测量:为何、如何以及何时?
Curr Opin Crit Care. 2018 Jun;24(3):209-215. doi: 10.1097/MCC.0000000000000503.
8
Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment.急性呼吸窘迫综合征:诊断与治疗的进展。
JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907.
9
Association of Driving Pressure With Mortality Among Ventilated Patients With Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.有创机械通气患者急性呼吸窘迫综合征患者驱动压与死亡率的相关性:系统评价和荟萃分析。
Crit Care Med. 2018 Feb;46(2):300-306. doi: 10.1097/CCM.0000000000002838.
10
Formulation and delivery strategies of ibuprofen: challenges and opportunities.布洛芬的制剂与给药策略:挑战与机遇
Drug Dev Ind Pharm. 2018 Feb;44(2):173-183. doi: 10.1080/03639045.2017.1391838. Epub 2017 Oct 30.